Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C10H14N2O4 |
| Molecular Weight | 226.2292 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O
InChI
InChIKey=VNLMRPAWAMPLNZ-UHFFFAOYSA-N
InChI=1S/C10H14N2O4/c1-3-4-10(5-6(2)13)7(14)11-9(16)12-8(10)15/h3,6,13H,1,4-5H2,2H3,(H2,11,12,14,15,16)
| Molecular Formula | C10H14N2O4 |
| Molecular Weight | 226.2292 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Proxibarbal is a non-sedative barbiturate with a specific anti-serotonin and anti-histamine effect, due to enzyme induction of serotoninase and histaminase. Its lack of unpleasant side-effects. Proxibarbal exists in ring-chain tautomeric equilibrium with the two diastereomers of valofan. Proxibarbal is metabolized to a five-membered lactone. Its only barbituric property is its ability to induce enzymes that destroy a surplus of neurohormones and rid people of their neurovegetative sufferings, including migraine and other types of vascular headache. Side effects are: dizziness, drowsiness, dyspepsia, allergic reactions. Proxibarbal enhances the effects of other depriving agents, including alcohol.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:08:41 GMT 2025
by
admin
on
Mon Mar 31 23:08:41 GMT 2025
|
| Record UNII |
Y54BSX54CS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Y54BSX54CS
Created by
admin on Mon Mar 31 23:08:41 GMT 2025 , Edited by admin on Mon Mar 31 23:08:41 GMT 2025
|
PRIMARY | |||
|
42013-22-9
Created by
admin on Mon Mar 31 23:08:41 GMT 2025 , Edited by admin on Mon Mar 31 23:08:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> ENANTIOMER |
|